A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy

Zheyu Shen, Wei Wei, Hideyuki Tanaka, Kazuhiro Kohama, Guanghui Ma, Toshiaki Dobashi, Yasuyuki Maki, Honghui Wang, Jingxiu Bi, Sheng Dai

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

In order to minimize the side effect of cancer chemotherapy, a novel galactosamine-mediated drug delivery carrier, galactosamine-conjugated albumin nanoparticles (GAL-AN), was developed for targeted liver cancer therapy. The albumin nanoparticles (AN) and doxorubicin-loaded AN (DOX-AN) were prepared by the desolvation of albumin in the presence of glutaraldehyde crosslinker. Morphological study indicated the spherical structure of these synthesized particles with an average diameter of around 200 nm. The functional ligand of galactosamine (GAL) was introduced onto the surfaces of AN and DOX-AN via carbodiimide chemistry to obtain GAL-AN and GAL-DOX-AN. Cellular uptake and kinetic studies showed that GAL-AN is able to be selectively incorporated into the HepG2 cells rather than AoSMC cells due to the existence of asialoglycoprotein receptors on HepG2 cell surface. The cytotoxicity, measured by MTT test, indicated that AN and GAL-AN are non-toxic and GAL-DOX-AN is more effective in HepG2 cell killing than that of DOX-AN. As such, our results implied that GAL-AN and GAL-DOX-AN have specific interaction with HepG2 cells via the recognition of GAL and asialoglycoprotein receptor, which renders GAL-AN a promising anticancer drug delivery carrier for liver cancer therapy.

Original languageEnglish
Pages (from-to)410-419
Number of pages10
JournalPharmacological Research
Volume64
Issue number4
DOIs
Publication statusPublished - Oct 1 2011
Externally publishedYes

Fingerprint

Galactosamine
Drug Carriers
Liver Neoplasms
Nanoparticles
Albumins
Doxorubicin
Hep G2 Cells
Therapeutics
Asialoglycoprotein Receptor
Carbodiimides
Glutaral

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Shen, Z., Wei, W., Tanaka, H., Kohama, K., Ma, G., Dobashi, T., ... Dai, S. (2011). A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy. Pharmacological Research, 64(4), 410-419. https://doi.org/10.1016/j.phrs.2011.06.015

A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy. / Shen, Zheyu; Wei, Wei; Tanaka, Hideyuki; Kohama, Kazuhiro; Ma, Guanghui; Dobashi, Toshiaki; Maki, Yasuyuki; Wang, Honghui; Bi, Jingxiu; Dai, Sheng.

In: Pharmacological Research, Vol. 64, No. 4, 01.10.2011, p. 410-419.

Research output: Contribution to journalArticle

Shen, Z, Wei, W, Tanaka, H, Kohama, K, Ma, G, Dobashi, T, Maki, Y, Wang, H, Bi, J & Dai, S 2011, 'A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy', Pharmacological Research, vol. 64, no. 4, pp. 410-419. https://doi.org/10.1016/j.phrs.2011.06.015
Shen, Zheyu ; Wei, Wei ; Tanaka, Hideyuki ; Kohama, Kazuhiro ; Ma, Guanghui ; Dobashi, Toshiaki ; Maki, Yasuyuki ; Wang, Honghui ; Bi, Jingxiu ; Dai, Sheng. / A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy. In: Pharmacological Research. 2011 ; Vol. 64, No. 4. pp. 410-419.
@article{4c60f493cc5f48edbbb05d4369e9fb96,
title = "A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy",
abstract = "In order to minimize the side effect of cancer chemotherapy, a novel galactosamine-mediated drug delivery carrier, galactosamine-conjugated albumin nanoparticles (GAL-AN), was developed for targeted liver cancer therapy. The albumin nanoparticles (AN) and doxorubicin-loaded AN (DOX-AN) were prepared by the desolvation of albumin in the presence of glutaraldehyde crosslinker. Morphological study indicated the spherical structure of these synthesized particles with an average diameter of around 200 nm. The functional ligand of galactosamine (GAL) was introduced onto the surfaces of AN and DOX-AN via carbodiimide chemistry to obtain GAL-AN and GAL-DOX-AN. Cellular uptake and kinetic studies showed that GAL-AN is able to be selectively incorporated into the HepG2 cells rather than AoSMC cells due to the existence of asialoglycoprotein receptors on HepG2 cell surface. The cytotoxicity, measured by MTT test, indicated that AN and GAL-AN are non-toxic and GAL-DOX-AN is more effective in HepG2 cell killing than that of DOX-AN. As such, our results implied that GAL-AN and GAL-DOX-AN have specific interaction with HepG2 cells via the recognition of GAL and asialoglycoprotein receptor, which renders GAL-AN a promising anticancer drug delivery carrier for liver cancer therapy.",
author = "Zheyu Shen and Wei Wei and Hideyuki Tanaka and Kazuhiro Kohama and Guanghui Ma and Toshiaki Dobashi and Yasuyuki Maki and Honghui Wang and Jingxiu Bi and Sheng Dai",
year = "2011",
month = "10",
day = "1",
doi = "10.1016/j.phrs.2011.06.015",
language = "English",
volume = "64",
pages = "410--419",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy

AU - Shen, Zheyu

AU - Wei, Wei

AU - Tanaka, Hideyuki

AU - Kohama, Kazuhiro

AU - Ma, Guanghui

AU - Dobashi, Toshiaki

AU - Maki, Yasuyuki

AU - Wang, Honghui

AU - Bi, Jingxiu

AU - Dai, Sheng

PY - 2011/10/1

Y1 - 2011/10/1

N2 - In order to minimize the side effect of cancer chemotherapy, a novel galactosamine-mediated drug delivery carrier, galactosamine-conjugated albumin nanoparticles (GAL-AN), was developed for targeted liver cancer therapy. The albumin nanoparticles (AN) and doxorubicin-loaded AN (DOX-AN) were prepared by the desolvation of albumin in the presence of glutaraldehyde crosslinker. Morphological study indicated the spherical structure of these synthesized particles with an average diameter of around 200 nm. The functional ligand of galactosamine (GAL) was introduced onto the surfaces of AN and DOX-AN via carbodiimide chemistry to obtain GAL-AN and GAL-DOX-AN. Cellular uptake and kinetic studies showed that GAL-AN is able to be selectively incorporated into the HepG2 cells rather than AoSMC cells due to the existence of asialoglycoprotein receptors on HepG2 cell surface. The cytotoxicity, measured by MTT test, indicated that AN and GAL-AN are non-toxic and GAL-DOX-AN is more effective in HepG2 cell killing than that of DOX-AN. As such, our results implied that GAL-AN and GAL-DOX-AN have specific interaction with HepG2 cells via the recognition of GAL and asialoglycoprotein receptor, which renders GAL-AN a promising anticancer drug delivery carrier for liver cancer therapy.

AB - In order to minimize the side effect of cancer chemotherapy, a novel galactosamine-mediated drug delivery carrier, galactosamine-conjugated albumin nanoparticles (GAL-AN), was developed for targeted liver cancer therapy. The albumin nanoparticles (AN) and doxorubicin-loaded AN (DOX-AN) were prepared by the desolvation of albumin in the presence of glutaraldehyde crosslinker. Morphological study indicated the spherical structure of these synthesized particles with an average diameter of around 200 nm. The functional ligand of galactosamine (GAL) was introduced onto the surfaces of AN and DOX-AN via carbodiimide chemistry to obtain GAL-AN and GAL-DOX-AN. Cellular uptake and kinetic studies showed that GAL-AN is able to be selectively incorporated into the HepG2 cells rather than AoSMC cells due to the existence of asialoglycoprotein receptors on HepG2 cell surface. The cytotoxicity, measured by MTT test, indicated that AN and GAL-AN are non-toxic and GAL-DOX-AN is more effective in HepG2 cell killing than that of DOX-AN. As such, our results implied that GAL-AN and GAL-DOX-AN have specific interaction with HepG2 cells via the recognition of GAL and asialoglycoprotein receptor, which renders GAL-AN a promising anticancer drug delivery carrier for liver cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=80052969743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052969743&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2011.06.015

DO - 10.1016/j.phrs.2011.06.015

M3 - Article

C2 - 21723392

AN - SCOPUS:80052969743

VL - 64

SP - 410

EP - 419

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 4

ER -